KLSC is honored to be invited to at the  Blockchain in Healthcare Symposium due to be held on Wednesday, the 9th of Deceber 2020.

Dr. Mussaad M. Al-Razouki will be speaking on "Blockchain in Healthcare, Opportunities, and challenges: Post Pandemic"

Healthcare will be part of the most aggressive industries worldwide implementing/driving blockchain technology. The Blockchain is the future business model of supply chain and has the potential to be applied to the entire healthcare value chain by streamlining and transforming everything from medical records, to payments and processing, and predictive (Big Data) analytics while benefitting virtually all its stakeholders from patients and customers to providers, administrators, and institutions.

#VBIH2020 offers healthcare professionals an opportunity to understand how blockchain technology can harness the capabilities in healthcare by consuming the knowledge from Blockchain experts, who are striving hard to make blockchain a valuable tool for healthcare industry in present & future pandemics.

We invite all the health care professionals to be a part of Virtual Blockchain in Healthcare Symposium 2020 on 9th December 2020, to unlock the buzzword of “Blockchain” in health care industry.

-Ends-

About KLSC:

Kuwait Life Sciences (KLSC) was established in 2010, with a paid-up capital of 18 million Kuwait Dinars (KD) which is equivalent to approximately $60 million US Dollars. KLSC is fully owned by National Technology Enterprises Company. National Technology Enterprises Company (NTEC) was incorporated in November of 2002, by the Kuwait Council of Ministers as a fully owned company by the Kuwait Investment Authority (KIA), the sovereign wealth fund of the State of Kuwait. Capitalized at 100 million Kuwait Dinars (KD) which is equivalent to approximately $350 million US Dollars, NTEC aims to play a vital role in servicing major stakeholders in Kuwait and the Middle East region with their technology requirements.

KLSC focuses on healthcare innovative concepts and demanded services that have a clear and unmet need in the Middle East and North Africa (MENA) region. KLSC has been designed as an integrated healthcare company building unique projects and is considered one of the pioneer venture capitalist and private equity companies in the Middle East that invests globally and operates regionally seeking to advance healthcare services and systems within the region. KLSC supports both public and private sector stakeholders to access emerging technologies, establish unique projects and adopt best practices prevailing in today’s healthcare field. KLSC operates in healthcare investment, life sciences training, medical technology, and pharmaceutical distribution.

For Further Press Enquiries:  
Email KLSC at: info@klsc.com.kw 

Send us your press releases to pressrelease.zawya@refinitiv.com

© Press Release 2020

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.